


Tifenazoxide

Cat. No.:	HY-119322		
CAS No.:	279215-43-9		
Molecular Formula:	C ₉ H ₁₀ ClN ₃ O ₂ S ₂		
Molecular Weight:	291.78		
Target:	Potassium Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (342.72 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.4272 mL	17.1362 mL	34.2724 mL
		5 mM	0.6854 mL	3.4272 mL	6.8545 mL
10 mM		0.3427 mL	1.7136 mL	3.4272 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.57 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.57 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.57 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ^{ATP} channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis ^{[1][2]} .
IC₅₀ & Target	K ^{ATP} channels ^{[1][2]}
In Vitro	Tifenazoxide (NN414) hyperpolarises βTC3 cell membranes, and inhibits insulin release from βTC6, from isolated rat islets

and from human islets at least a 100-fold more potent than Diazoxide^[2].

The EC₅₀ values for Tifenazoxide and diazoxide are 0.45 and 31 μM, respectively in the patch-clamp assay. Tifenazoxide (100 μM) activates Kir6.2/SUR1 channels, but not Kir6.2/SUR2A or Kir6.2/SUR2 channels, expressed in *Xenopus* oocytes both in whole-cell and inside-out macropatch recordings^[2].

Tifenazoxide is a potent inhibitor of glucose stimulated insulin release from βTC6 cells (IC₅₀ = 0.15 μM)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tifenazoxide (NN414; 1.5 mg/kg; oral administration; twice daily; for 3 weeks; male VDF Zucker (fa/fa) rat) treatment for 3 weeks in VDF rats reduces basal hyperglycemia, improves glucose tolerance, and reduces hyperinsulinemia during an oral glucose tolerance test (OGTT) and improves insulin secretory responsiveness *ex vivo*^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Vancouver diabetic fatty (VDF) Zucker rat ^[1]
Dosage:	1.5 mg/kg
Administration:	Oral administration; twice daily; for 3 weeks
Result:	Basal glucose was significantly reduced with the fall averaging 0.64 mM after 3 weeks of treatment.

REFERENCES

[1]. Carr RD, et al. NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. *Diabetes*. 2003 Oct;52(10):2513-8.

[2]. Hansen JB. Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. *Curr Med Chem*. 2006;13(4):361-76.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA